ProPhase Labs Files 8-K on Financials
Ticker: PRPH · Form: 8-K · Filed: May 9, 2024 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | May 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
ProPhase Labs dropped an 8-K detailing financial results and operations.
AI Summary
ProPhase Labs, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Quigley Corp, is incorporated in Delaware and headquartered in Garden City, New York.
Why It Matters
This 8-K filing provides investors with crucial updates on ProPhase Labs' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer
- Quigley Corp (company) — Former Company Name
- May 9, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Garden City, New York (location) — Principal Executive Offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
When was ProPhase Labs, Inc. previously known as Quigley Corp?
The date of the name change from Quigley Corp to ProPhase Labs, Inc. was March 28, 1993.
What is the primary business of ProPhase Labs, Inc. according to its SIC code?
The Standard Industrial Classification (SIC) code for ProPhase Labs, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where are ProPhase Labs, Inc.'s principal executive offices located?
The principal executive offices are located at 711 Stewart Avenue, Suite 200, Garden City, New York 11530.
What is the SEC file number for ProPhase Labs, Inc.?
The SEC file number for ProPhase Labs, Inc. is 000-21617.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-05-09 08:05:43
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 175KB
- 0001493152-24-018333.txt ( ) — 404KB
- prph-20240509.xsd (EX-101.SCH) — 3KB
- prph-20240509_lab.xml (EX-101.LAB) — 33KB
- prph-20240509_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 711 Stewart Avenue , Suite 200 Garden 11530 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (215) 345-0919 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On May 9, 2024, ProPhase Labs, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 7.01 Regulation FD. As previously announced, the Company will conduct a conference call today, Thursday, May 9, 2024, at 11:00 a.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments. The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits No. Description 99.1 Press Release dated May 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: May 9, 2024